I’ve speculated often about Hikma’s decline. Is it a voluntary business or legal decision? What would these business or legal decisions be based on. Maybe they just got priced out by completion. Or is it part of something else we’re unaware of? I have no reason to believe DRL or Apotex will follow Hikma’s pattern unless it’s legally driven or a business decision based on the recent significant formulary coverage changes that will impact their scripts growth. Are they willing to invest the money to increase manufacturing and supply contracts given the significant formulary changes in the US that either removed GV from coverage or placed GV and V on the same low tier/copay and removed PA’s? I can’t figure out Apotex. It’s a head scratcher. How are they growing while other generics are shrinking or stagnating? I believe AMRN will gradually increase scripts from here and continue to take scripts that went to generics prior to the formulary changes. Sorry for the long post. I wanted to address all your thoughts because I think they’re hugely important to AMRN success in the US. Thanks for the script numbers.
Market Data 
Markets 
AI
